Source:http://linkedlifedata.com/resource/pubmed/id/16179371
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2006-2-7
|
pubmed:abstractText |
We investigated the clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria (PNH)-type blood cells in patients with acquired aplastic anemia (AA). We quantified CD55-CD59- granulocytes and red blood cells (RBCs) in peripheral blood from 122 patients with recently diagnosed AA and correlated numbers of PNH-type cells and responses to immunosuppressive therapy (IST). Flow cytometry detected 0.005% to 23.1% of GPI-AP- cells in 68% of patients with AA. Sixty-eight of 83 (91%) patients with an increased proportion of PNH-type cells (PNH+) responded to antithymocyte globulin (ATG) + cyclosporin (CsA) therapy, whereas 18 of 39 (48%) without such an increase (PNH-) responded. Failure-free survival rates were significantly higher (64%) among patients with PNH+ than patients with PNH- (12%) at 5 years, although overall survival rates were comparable between the groups. Numbers of PNH-type and normal-type cells increased in parallel among most patients with PNH+ who responded to IST, suggesting that these cells are equally sensitive to immune attack. These results indicate that a minor population of PNH-type cells represents a reliable marker of a positive IST response and a favorable prognosis among patients with AA. Furthermore, immune attack against hematopoietic stem cells that allows PNH clonal expansion might occur only at the onset of AA.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD55,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD59,
http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
107
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1308-14
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16179371-Adolescent,
pubmed-meshheading:16179371-Adult,
pubmed-meshheading:16179371-Aged,
pubmed-meshheading:16179371-Aged, 80 and over,
pubmed-meshheading:16179371-Anemia, Aplastic,
pubmed-meshheading:16179371-Antigens, CD,
pubmed-meshheading:16179371-Antigens, CD55,
pubmed-meshheading:16179371-Antigens, CD59,
pubmed-meshheading:16179371-Antilymphocyte Serum,
pubmed-meshheading:16179371-Chromosome Aberrations,
pubmed-meshheading:16179371-Cyclosporine,
pubmed-meshheading:16179371-Female,
pubmed-meshheading:16179371-Flow Cytometry,
pubmed-meshheading:16179371-Granulocytes,
pubmed-meshheading:16179371-Humans,
pubmed-meshheading:16179371-Immunosuppressive Agents,
pubmed-meshheading:16179371-Leukocyte Count,
pubmed-meshheading:16179371-Male,
pubmed-meshheading:16179371-Middle Aged,
pubmed-meshheading:16179371-Predictive Value of Tests,
pubmed-meshheading:16179371-Survival Analysis
|
pubmed:year |
2006
|
pubmed:articleTitle |
Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia.
|
pubmed:affiliation |
Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|